Navigation Links
Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs

PARSIPPANY, N.J., Feb. 11 /PRNewswire-FirstCall/ -- Daiichi Sankyo, Inc. (DSI) announced today that Jay M. Feingold, M.D., Ph.D., has been appointed Vice President of Medical Affairs. Dr. Feingold will manage strategic direction of the company's Medical Affairs department and oversee more than 90 scientists, researchers and field-based medical teams responsible for collaborating with the company's clinical research arm, commercial organization and partners. Medical Affairs is responsible for providing physicians, key opinion leaders, regulatory agencies and professional organizations with medical and scientific information in the areas of clinical studies, outcomes research and disease management programs, among others. Dr. Feingold's vast experience in oncology and hematology will continue to drive the company's current cardiovascular portfolio and shape its pipeline.

"I am very excited to join Daiichi Sankyo and look forward to working with my colleagues to continue to build relationships with health care providers to improve medical care and enhance professional education," said Dr. Feingold. "As we develop new and innovative therapies it will be important to ensure that critical safety and efficacy information is understood by practitioners, regulatory agencies, payors and patients. Medical Affairs plays a key role in communicating this information."

Dr. Feingold also becomes a member of DSI's Executive Committee, which is responsible for guiding the organization's short- and long-term strategic and financial objectives.

DSI is the U.S. subsidiary of Tokyo-based Daiichi Sankyo Co., Ltd. The U.S. headquarters facility in Parsippany, New Jersey houses 480 employees, including corporate offices and all functions that support the company's commercial operations. In addition, the company has a clinical development division in Edison, New Jersey that employs 350 people who oversee clinical trials being conducted around the world.    

Prior to joining DSI, Dr. Feingold worked with Wyeth Pharmaceuticals, where he most recently led Oncology Global Clinical Development.  Prior to that, he was multi-therapeutic area head in Global Medical Affairs with responsibility for the hematology, oncology and central nervous system (CNS) franchises.

Dr. Feingold, a member of the American Society of Hematology and American Society of Clinical Oncology, is a molecular biologist who earned his Bachelor of Science degree from S.U.N.Y. Stony Brook and his Medical Degree, Master of Science and Ph.D. degrees from Albert Einstein College of Medicine.  Dr. Feingold did his residency in Pediatrics and fellowship in Pediatric Hematology/Oncology at the UCLA Center for the Health Sciences.

About Daiichi Sankyo, Inc.

Daiichi Sankyo Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Tokyo-based Daiichi Sankyo Co., Ltd., which is a global pharmaceutical innovator.  The headquarters company was established in 2005 from the merger of two leading Japanese pharmaceutical companies.  This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research

and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes and acute coronary syndrome. Also important to the company is the discovery of new medicines in the areas of infectious diseases, cancer, bone and joint diseases, and immune disorders. For more information, visit

SOURCE Daiichi Sankyo, Inc.



SOURCE Daiichi Sankyo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
2. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
3. Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
4. Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
5. Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation
7. KGI Names Kerry Howell Vice President for Advancement
8. Vical Names Andrew de Guttadauro Vice President, Corporate Development
9. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. CryoLife Names Philip Theodore as Vice President, General Counsel
Post Your Comments:
(Date:11/30/2015)... Harvard Apparatus Regenerative Technology, Inc. (HART) ... bioengineered organ implants for life-threatening conditions, today announced ... Stock Market that it has regained compliance with ... that as a result of the closing bid ... per share for more than ten consecutive business ...
(Date:11/30/2015)...  Champions Oncology, Inc. (CSBR), engaged in the development ... development and use of oncology drugs, today announced that ... presenting at the LD MICRO Investor Conference on Wednesday, ... The conference, held at the Luxe Sunset Bel Air ... will feature 200 small/micro-cap companies and is expected to ...
(Date:11/30/2015)... , Nov. 30, 2015  Aytu BioScience, Inc. ... urological and related conditions, will present at two upcoming ..., an interactive real-time virtual conference, to be held ... Investor Conference, to be held December 2 nd ... Angeles and streamed live via webcast. ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... software integration with MarkLogic, the Enterprise NoSQL database platform provider, creating a ... change. , Smartlogic’s Content Intelligence capabilities provide a robust set of semantic ...
Breaking Biology Technology:
(Date:11/18/2015)... --> --> ... report titled  Gesture Recognition Market - Global Industry Analysis, ... to the report, the global gesture recognition market was valued at ... US$29.1 bn by 2021, at a CAGR of 20.3% ... dominated the global gesture recognition market in ...
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
Breaking Biology News(10 mins):